Week In Review: Sinopharm Transfers $4.6 Billion In Assets, Including Two COVID-19 Vaccines

Sinopharm Group will transfer six of its vaccine companies to Beijing Tiantan Biological Products. Two of the transferring companies have approved COVID-19 vaccines, and Sinopharma said a public listing will facilitate additional sources of funding.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.